亚洲v日韩v精品v无码专区_精选国产av精选一区二区_欧美日本一道高清国产_夜夜欢天天干_亚洲国产一成人久久精品,天天操天天干天天摸天天日天天插天无想,亚洲国产欧美日韩在线,靠靠操操网

US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Haitian Flav
03288.HK		 Food Additives 35-36.3 100 3,667 2025/06/16 2025/06/18 2025/06/19
Sanhua
02050.HK		 N/A 21.21-22.53 100 2,276 2025/06/18 Data is not available 2025/06/23
Bayzed Health
02609.HK		 N/A 4.22-6.75 600 4,091 2025/06/18 Data is not available 2025/06/23
TransThera-B
02617.HK		 N/A 13.15 500 N/A 2025/06/18 Data is not available 2025/06/23
Summary
We are a leader in the bioactive ingredient-based professional skin treatment product industry in China. We design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. We also develop and manufacture rare ginsenosides technology-based functional foods. We utilize proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

The skin-related beauty sector comprises (i) skin care and treatment, and (ii) skin rejuvenation applications. Further, skin care and treatment includes (i) general skincare, (ii) functional skincare and (iii) medical dressings, with the latter two constituting the professional skin treatment sector. The overall skin care and treatment market in China was very fragmented in 2021. See “– Market Landscape.” According to Frost & Sullivan, our market share was approximately 1.1 % of China’s overall skin care and treatment market in terms of retail sales in 2021. Within this market during the Track Record Period, we primarily focused on the professional skin treatment product market, including functional skincare products and medical dressings. Professional skin treatment products are used to address various skin issues, such as skin sensitivity, premature skin aging, chronic eczema and allergies, and can also be used for general skincare of consumers. China’s overall professional skin treatment product market in terms of retail sales value was RMB56.6 billion in 2021. In addition, certain of our pipeline products target skin rejuvenation applications.

Our years of R&D on bioactive ingredients and integrated business model enable us to achieve the technological and market leadership positions in the industry. According to Frost & Sullivan:

? We were the second-largest professional skin treatment product company in China in 2021 with a retail sales value of RMB6.0 billion as well as the largest collagen-based professional skin treatment product company by retail sales in China for the latest three consecutive years since 2019;

? Collgene (可麗金) and Comfy (可復(fù)美), our flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively, with a retail sales value of RMB2.9 billion and RMB2.7 billion, respectively, in China in 2021;

? Our proprietary recombinant collagen technology was the first in its field to be awarded a patent in China; and

? We are the first company to obtain a medical device registration for recombinant collagen-based product in China.

As of the Latest Practicable Date, we had a portfolio of 105 SKUs across eight major brands covering functional skincare, medical dressings and functional foods, namely Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan.

We have achieved significant growth during the Track Record Period. Our revenue increased from RMB956.7 million in 2019 to RMB1,190.5 million in 2020, and further increased to RMB1,552.5 million in 2021. Our revenue increased from RMB520.6 million for the five months ended May 31, 2021 to RMB723.0 million for the same period in 2022. Moreover, our net profit amounted to RMB575.2 million, RMB826.5 million, RMB828.1 million and RMB313.6 million in 2019, 2020, 2021 and the five months ended May 31, 2022, respectively, with net margin of 60.1%, 69.4%, 53.3% and 43.4% during the same periods. The overall decline in our net margin during the Track Record Period was mainly attributable to the increase in online marketing expenses, resulting from the continuous expansion of our online sales channels as we increased spending on online sales and marketing activities on e-commerce platforms and social media platforms to follow industry trends and capture market opportunities. Our adjusted net profit (non-IFRS measure) amounted to RMB575.2 million, RMB827.1 million, RMB851.3 million and RMB336.1 million in 2019, 2020, 2021 and the five months ended May 31, 2022, respectively, with adjusted net profit margin (non-IFRS measure) of 60.1%, 69.5%, 54.8% and 46.5% during the same periods.



Source: Giant Biogene (02367) Prospectus (IPO Date : 2022/10/25)
Listing Market MAIN
Industry Beauty & Toiletries Products and Services
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders Fan Daidi (55.03%)
Directors Yan Jianya (Chairman and Chief Executive Officer and Executive Director)
Fang Juan (Senior Vice President and Executive Director)
Ye Juan (Senior Vice President and Executive Director)
Yan Yubo (Executive Director)
Zhang Huijuan (Executive Director)
Huang Jin (Independent Non-Executive Director)
Shan Wenhua (Independent Non-Executive Director)
Wong Sze Wing (Independent Non-Executive Director)
Company Secretary Yan Yubo
Yuen Wing Yan, Winnie
Principal Bankers China Merchants Bank
Shanghai Pudong Development Bank Co., Ltd.
Chang’an Bank Co., Limited
Solicitors Clifford Chance
Maples and Calder (Hong Kong) LLP
Auditors Ernst & Young
Registered Office Room 1922, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://www.xajuzi.com
Email Address [email protected]
Tel No (86 29) 8115-6502
Fax No
 
SITEMAP
Email: [email protected]
AASTOCKS.COM LIMITED (阿斯達(dá)克網(wǎng)絡(luò)信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright ? 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.